Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532428 · ClinicalTrials.gov registry record · Phase 4
Long Term Effects of Raloxifene Treatment on Bone Quality
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00532428 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 31 participants.
The verdict
NCT00532428, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.
Interventions
- DRUG Placebo
- DRUG Raloxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2003-04 |
| Est. Completion | 2003-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532428
The ClinicalTrials.gov registry entry for NCT00532428 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00532428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532428 about?
NCT00532428 is a clinical study titled "Long Term Effects of Raloxifene Treatment on Bone Quality". This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.
What is the current status of trial NCT00532428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2003-04. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00532428?
The interventions under investigation include: Placebo (DRUG), Raloxifene (DRUG).
Who is sponsoring clinical trial NCT00532428?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.